Key Takeaways
- Record EBITDA, milestone PAT: Quarterly EBITDA crossed INR110 crores for the first time, and H1 PAT of INR91 crores already surpassed all of FY25, driven by a 60% surge in base formulation volumes.
- The pipeline is converting to revenue: Licensing income fell as products moved from development to commercial supply, a deliberate shift that management says is the point of the pipeline.
- NorUDCA is the new growth axis: The first-in-India NCE launch opens a novel NAFLD market, with API supplies starting Q3 and "sizable" formulation revenue expected next fiscal.
- Margins are structurally improving: Gross margin hit 72% despite lower high-margin licensing, and adjusted ROCE jumped from 4% in FY23 to ~17% in H1, proving the base business can carry profitability.
- What to watch next quarter: NorUDCA API supply ramp, Ursodeoxycholic Acid commercial start, and any update on the Jadcherla USFDA inspection that management declined to discuss.
The Quarter: What Drove the Breakthrough
- Base formulation business delivered the beat: Excluding licensing income, formulation revenue grew ~60% YoY for the quarter and 67% for H1, powered by increasing market share of complex products in the U.S. and limited-competition products in Europe.
- API volumes scaled with capacity: Non-captive API turnover reached INR205 crores as newly expanded capacities drove higher offtake of key products, with Tranexamic Acid volumes growing every quarter and expected to hit full utilization this year.
- Nilotinib is the European anchor: The differentiated product launched last year continues to gain market share every quarter, with no significant generic competition expected in the current quarter.
- Licensing income fell, and that is the plan: Products that generated licensing fees last year have moved to commercial supply, so revenue shifted from lumpy licensing to recurring commercial sales. Management does not compare licensing quarter-to-quarter because it is "lopsided" by nature.
- Biologics revenue was INR25 crores for the quarter, with Adalimumab contributing modestly in India but serving as a confidence-building launch for the platform.
Keshav Bhutada: "The current quarter marks a very big breakthrough for us. We recorded highest quarterly EBITDA, and the excitement is not only to share another set of results, but to share the momentum, the confidence and the direction that the company is focusing on ensuring better asset utilization."
NorUDCA: The First NCE, and a Global Ambition
- First-to-market in India: Shilpa is the only company globally to launch NorUrsodeoxycholic acid, targeting the NAFLD treatment market where management estimates capturing 10–20% share.
- Revenue trajectory: Q3 and Q4 will see initial supplies; "sizable numbers" are expected from next financial year. The company has partnered with around three firms and will not add more, to avoid partner competition.
- API supplies begin Q3 FY26, with meaningful contribution expected next fiscal. The company also plans to take NorUDCA to global markets.
- European clinical studies for NorUDCA will start next financial year.
Keshav Bhutada: "I think we don't want to have a lot of partners who inturn would compete among each other. So it's more a strategic partnering what we have done for the product."
Pipeline: What Is Coming, and When
Near-term commercial triggers
| Product | Trigger | Timeline |
|---|---|---|
| Ursodeoxycholic Acid | Commercial supplies start | Q3 FY26 |
| NorUDCA API | Commercial supplies start | Q3 FY26 |
| NCE program (big pharma partner) | First product commercial supplies | Q4 FY26 |
| Rotigotine transdermal patch | U.S. submission; approval | Q3 FY26; Q4 FY26 |
| Ondansetron long-acting injection | India filing; launch | Q4 FY26; next FY |
| Semaglutide | PV campaign complete; filing | Q4 FY26; H1 FY27 |
| Lanthanum Dioxycarbonate (Unicycive) | Block commissioning; commercial launch | Q3 FY26; next FY |
Medium-term pipeline milestones
- Recombinant Human Albumin: European Phase III clinical studies planned to start Q4 FY26; IMPD submission on track.
- Nivolumab: Phase I/III clinical trial in India likely to start Q4 FY26.
- Two NBE programs (with mAbTree and Alveolus) and the first ADC biosimilar are all expected to enter human studies in FY27.
- Aflibercept: The most advanced biosimilar, currently in Phase III; launch expected in FY27 if clinical studies succeed. U.S. and Europe Phase III will follow later in FY27.
- Androgenic Alopecia program: Phase II completed over 15 months ago; additional preclinical studies recently finished; Phase III applied for, expected to start in H1 next financial year.
- Peptide project with MNC: Pilot quantities supplied; commercialization expected in calendar 2027. Shilpa has invested in R&D over 3–5 years and now has two manufacturing lines.
- Semaglutide positioning: Management acknowledges being a late entrant but is building end-to-end backward integration across synthetic and semisynthetic API plus formulation, aiming to stay competitive on cost.
Alpesh Dalal: "I'm happy to report that the PAT that we have achieved in the first half has surpassed our full year PAT in FY '25, which was at INR78 crores."
European Strategy: Complex, Not Commodity
- The me-too trap: Management is explicit that competing with me-too generics in Europe means big competition and no market share. Growth requires complex generics and differentiated, early non-infringing formulations.
- Nilotinib proves the model: The differentiated product launched last year is the major European revenue driver, gaining share every quarter with no significant generic threat in sight.
- Pipeline alignment: Products like Rotigotine transdermal patch, Ondansetron long-acting injection, and other 505(b)(2) programs are built for this differentiated strategy.
Keshav Bhutada: "if you just go with me-too generics, then there is a big competition, and you cannot get market share. So in Europe, if we really want to grow and increase our market share we need to focus more on complex generics and differentiated early non-infringing formulations."
Financial Health: Margins, Returns, and Capex
- Gross margin improved to 72% for the quarter and 74% for H1, despite a lower contribution from the high-margin CDMO and licensing business compared to last year. The base business margin is strengthening as complex product volumes scale.
- EBITDA margin reached 30% for both the quarter and H1, a 4% and 3% YoY improvement respectively.
- ROCE transformation: Adjusted ROCE, excluding Biologics and NBE investments, improved from 4% in FY23 to approximately 17% in H1 FY26. Management is confident of further operating leverage from an improving business mix.
- Interest outgo has stabilized at current levels; most future capex is expected to be funded through internal accruals.
- Capex for FY27 will be updated around Q4, once the current capex cycle concludes.
- Profitability sustainability: The shift in business mix toward higher market share in base products plus novel launches like NorUDCA should sustain current profitability levels.
Unanswered Questions
- USFDA Jadcherla inspection: Management declined to provide any update, stating it will inform markets when there is something to share.
- API segment breakup excluding captive consumption was deferred to the investor relations contact.
- Biologics revenue split between Adalimumab sales and CDMO was not disclosed on the call.
- Licensing income from Orion Corporation for the Albumin contract was declined as client-confidential.
- NCE molecule indication and market size for the FY26 launch were not disclosed.
- Peptide project details with the MNC partner were not shared.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API business growth | Double-digit YoY growth | Ongoing |
| Tranexamic Acid capacity | Achieve full utilization of current capacity | Current year |
| Tranexamic Acid expansion | Commission additional 100 MT capacity | Next financial year |
| Ursodeoxycholic Acid | Start commercial supplies | Q3 FY26 |
| NorUDCA API | Start commercial supplies; meaningful contribution | Q3 FY26; next FY |
| First NCE product (big pharma) | Start commercial supplies | Q4 FY26 |
| Rotigotine patch | U.S. submission; approval | Q3 FY26; Q4 FY26 |
| Semaglutide | Complete PV campaign; file | Q4 FY26; H1 FY27 |
| Lanthanum Dioxycarbonate | Commission dedicated block; commercial launch | Q3 FY26; next FY |
| Ondansetron long-acting injection | File in India; launch | Q4 FY26; next FY |
| OLC (Unicycive) | Approval; commercialization revenue | FY26; second half next FY |
| Recombinant Human Albumin | Start European Phase III | Q4 FY26 |
| Nivolumab | Start Phase I/III India trial | Q4 FY26 |
| Two NBE programs | Enter Phase I human studies | FY27 |
| First ADC biosimilar | Enter human studies | FY27 |
| Aflibercept | Launch (subject to clinical success) | FY27 |
| Androgenic Alopecia | Start Phase III | H1 next FY |
| Peptide project with MNC | Commercialization | Calendar 2027 |
| Interest outgo | Remain at current levels | Ongoing |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹372 cr, +7% YoY; highest ever quarterly revenue |
| H1 FY26 revenue | ₹700 cr, +8% YoY |
| Gross margin | 72% for the quarter, 74% for H1; improved despite lower CDMO and licensing contribution |
| EBITDA | ₹110 cr, +21% YoY vs ₹91 cr in Q2 FY25; highest ever quarterly EBITDA |
| H1 FY26 EBITDA | ₹208 cr, +20% YoY |
| EBITDA margin | 30% for the quarter and H1; +4 ppt YoY for Q2, +3 ppt YoY for H1 |
| PAT | ₹44 cr for the quarter; ₹91 cr for H1, surpassing full-year FY25 PAT of ₹78 cr |
| Adjusted ROCE (excl. biologics and NBE) | ~17% in H1 FY26, improved from 4% in FY23 |
| Non-captive API revenue | ₹205 cr |
| Formulation revenue | ₹109 cr, +16% YoY |
| Formulation base business growth (excl. licensing) | ~60% YoY for the quarter, 67% for H1 |
| Biologics revenue | ₹25 cr in Q2, ₹61 cr in H1 |
| Total service income (licensing and CDMO) | ₹72 cr; ₹46 cr from Formulation, ₹26 cr from API and Biologics (per an analyst's math) |
| H1 FY26 capex | ₹153 cr |
| Remaining FY26 capex estimate | ₹75–100 cr |